Kreston Reeves Advise A4P Consulting On Sale To LabConnect
Kreston Reeves has advised A4P Consulting on its sale to the US-based LabConnect.
A4P is headquartered in Discovery Park, Sandwich, Kent with a wholly owned subsidiary in Appenzell, Switzerland. With core expertise in regulated bioanalysis and genomics, biomarker strategy, personalised healthcare, biosample operations and bespoke logistics solutions, A4P serves a wide variety of clients across a broad range of therapeutic areas.
Partnering with pharmaceutical and biotechnology companies, contract research organisations and foundations/non-governmental organisations, LabConnect provides innovative Central Laboratory Services and scientific Functional Service Provider (FSP) Solutions for clinical trials of all sizes and complexity across the globe.
As the requirements for clinical trials and the drug development process have become more complex, LabConnect meets these requirements by offering researchers scientific and technical expertise for all laboratory-related needs, advising on strategies for lab data collection and providing end-to-end analytical and logistical solutions tailored to each trial.
The acquisition of A4P Consulting further solidifies LabConnect’s industry leading position as a provider of global central laboratory services and scientific-focused FSP Solutions.
Ian James, PhD., Co-Founder and Chief Executive Officer of A4P said: “A4P was founded over 12 years ago by four individuals from the pharma industry with a vision of how bioanalytical and logistical consultancy could be transformed. Bringing together our unique company model with LabConnect unlocks exciting opportunities to broaden the geographies we operate in and enhance our service offerings for our customers.
“I am excited for the future for both our customers and our valued staff, and grateful to the team at Kreston Reeves for bringing their experience and insights to get this deal across the line.”
The Kreston Reeves team advising A4P Consulting, also based at Discovery Park, was led by Partner Scott Mile and Business Advisory Manager Jak Hill, with tax advice from Director Michael Haig.
Dawn Sherman, Chief Executive Officer of LabConnect said: “With our complementary experience, expertise, and nimble working model, our clients have unprecedented access to leading edge scientific solutions to support their pre-clinical and clinical research. By joining forces with A4P, we further our mission to create healthier communities and improve patient lives by accelerating the development of medicines.”
LabConnect was advised by BroadOak Capital Partners and DLA Piper on the transaction. Advisors for A4P were Achelous Partners, Bishop and Sewell and Higson & Co.
